The FIGARO-DKD study

This study is looking for:

  • People aged 18 years and older who have T2D and have been diagnosed with diabetic kidney disease and are taking blood pressure medication

About this study

The purpose of the FIGARO-DKD study is to determine whether adding a new medication called finerenone to regular treatment is safe and effective to reduce cardiovascular complications, like heart disease or stroke, in patients with T2D and diabetic kidney disease (DKD).

The study will also look at whether the addition of finerenone to regular treatment may help slow the progression of kidney disease.